Carcinoma of bladder
|
0.500 |
CausalMutation
|
disease |
CGI |
|
|
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest.
|
19955487 |
2010 |
Carcinoma of bladder
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Bladder cancer cell lines were exposed to normoxic or hypoxic conditions and examined for the expression of FGFR3 by quantitative PCR (qPCR) and western blotting, and miR-100 by qPCR.
|
23778527 |
2013 |
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder.
|
14678961 |
2003 |
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
FGFR3 and Tp53 mutations have been proposed as defining two alternative pathways in the pathogenesis of transitional bladder cancer.
|
16061860 |
2005 |
Carcinoma of bladder
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer.
|
17668422 |
2007 |
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
FGFR3 analyses did not reveal any mutation in the urothelium from neither the control group nor the bladder cancer group.
|
19621447 |
2009 |
Carcinoma of bladder
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population.
|
20542753 |
2010 |
Carcinoma of bladder
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy.
|
24360661 |
2014 |
Carcinoma of bladder
|
0.500 |
Biomarker
|
disease |
BEFREE |
FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism.
|
24784839 |
2014 |
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
FGFR3 mutations are common in low-grade BC, while TP53 mutation or loss of RB1 is associated with muscle-invasive BC.
|
26924873 |
2016 |
Carcinoma of bladder
|
0.500 |
Biomarker
|
disease |
BEFREE |
Fibroblast growth factor receptor 3 (FGFR3) is an actionable target in bladder cancer.
|
27091807 |
2016 |
Carcinoma of bladder
|
0.500 |
Biomarker
|
disease |
BEFREE |
FGFR3-TACC3 fusion transcripts were identified by RNA-FISH and RT-PCR in mouse xenograft FFPE tissues using the human BC cell lines RT112 and RT4.
|
27930669 |
2016 |
Carcinoma of bladder
|
0.500 |
Biomarker
|
disease |
BEFREE |
FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study.
|
28049011 |
2017 |
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine.
|
16278395 |
2005 |
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Activating mutations of FGFR3 are a common and early event in bladder cancer.
|
25223521 |
2015 |
Carcinoma of bladder
|
0.500 |
Biomarker
|
disease |
BEFREE |
Activating point mutations and protein overexpression of fibroblast growth factor receptors (FGFRs), especially FGFR3, are frequent events in bladder cancer.
|
24898159 |
2015 |
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
An example of a TM domain pathogenic mutation is the Ala391-->Glu mutation in fibroblast growth factor receptor 3 (FGFR3), linked to Crouzon syndrome with acanthosis nigricans, as well as to bladder cancer.
|
16384584 |
2006 |
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Analysing only previously reported point mutations, TERT mutations were found in 55% of patients with bladder cancer (independent of stage), FGFR3 mutations in 30% of patients with bladder cancer, PIK3CA in 14% and TP53 mutations in 12% of patients with bladder cancer.
|
26901314 |
2016 |
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
CLINVAR |
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.
|
19381019 |
2009 |
Carcinoma of bladder
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis.
|
18413799 |
2008 |
Carcinoma of bladder
|
0.500 |
Biomarker
|
disease |
BEFREE |
As for FGFR3 in UCC, tumors with high FOXA1 expression have lower rates of progression than those with low expression (Log rank p=0.009).
|
25071007 |
2014 |
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.
|
22422578 |
2012 |
Carcinoma of bladder
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Conversely, FGFR3 over-expression was recently found in 40 % of muscle invasive BC.
|
24880661 |
2014 |
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
CLINVAR |
FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population.
|
20542753 |
2010 |